Interesting...good catch...they still plan on commercialization in the first quarter. That tells me they have the data, and are working on the financing to commercialize the tests. My prediction...they secure the financing, release the secured breast cancer patent news, release the positive Phase II results, and then release the financing news after a nice spike...to be real, we know the financing will most likely involve some sort of dilution...that is expected with a development-stage company moving into production/commercializing mode, but it will ultimately provide the needed funds for future growth, so it is good. Could see 0.50 real soon ;) with the run, financing drops it back to 0.30 (re-load time), and then runs to 1.00 plus (maybe more) into year-end on positive breast-cancer test news and commercialization. May be optimistic, but could easily happen...patience as this one is still undiscovered in the institution realm...they will come when revenues start coming in.
